Asth­ma pa­tients are un­fa­mil­iar with bi­o­log­ic brands, but open to try — Phree­sia sur­vey

Peo­ple liv­ing with asth­ma are open to try­ing new bi­o­log­ic treat­ments now on the mar­ket — they just haven’t heard of them. On­ly 5% have heard of Dupix­ent, Sanofi and Re­gen­eron’s mul­ti-in­di­ca­tion asth­ma and eczema block­buster, a new sur­vey from Phree­sia re­port­ed.

Con­sid­er­ing the fact that Dupix­ent spent more than half a bil­lion on ad­ver­tis­ing in 2021 — $524 mil­lion to be ex­act and the high­est me­dia spend­ing by any phar­ma brand in 2021 — that would seem to be a fair­ly low aware­ness num­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER